Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
Article Details
- CitationCopy to clipboard
Totah RA, Rettie AE
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
Clin Pharmacol Ther. 2005 May;77(5):341-52. doi: 10.1016/j.clpt.2004.12.267.
- PubMed ID
- 15900280 [ View in PubMed]
- Abstract
Cytochrome P450 (CYP) 2C8 [corrected] has been a relatively neglected member of the human CYP2C family. Over the period from 2000 through 2003, PubMed searches with the key word CYP2C8 returned only 10% to 15% of the citations obtained for all of the CYP2C enzymes combined. However, in the past year a crystal structure for CYP2C8 has been described, new inhibitors and probe substrates for the enzyme have been in development, the first case study was published linking CYP2C8 genetic polymorphisms to a disease state, and there has been an increasing awareness of the role that CYP2C8 plays in the disposition of therapeutic agents, especially from the pharmacogenetic and drug-drug interaction perspectives. This report discusses baseline characteristics of the enzyme and summarizes recent developments in these areas and their clinical relevance.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Verapamil Cytochrome P450 2C8 Protein Humans UnknownSubstrateInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAlmotriptanSecobarbital The metabolism of Almotriptan can be increased when combined with Secobarbital. AlmotriptanBexarotene The metabolism of Almotriptan can be decreased when combined with Bexarotene. AlmotriptanLoratadine The metabolism of Almotriptan can be decreased when combined with Loratadine. AlmotriptanMedroxyprogesterone acetate The metabolism of Almotriptan can be decreased when combined with Medroxyprogesterone acetate. AlmotriptanIrbesartan The metabolism of Almotriptan can be decreased when combined with Irbesartan.